dexcom glp-1 and CGM: Why Ozempic Users Are Turning to the Stelo (2026 – Pump Peelz DexCom Weighs GLP 1 CGM

Explore how the GLP-1 era is reshaping the food industry, driving demand for personalized nutrition, functional ingredients, and portion innovation.

Policymakers, insurers, and employers must weigh the benefits of expanding access to these effective medications against the potentiallyunsustainable coststhey introduce.

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

It hydrates skin, supports barrier function, increases cell volume to plump out skin, and circulates nutrients throughout the body

Here's what it means.